Amlodipine, a Ca2+ channel blocker, suppresses phosphorylation of epidermal growth factor receptor in human epidermoid carcinoma A431 cells

Life Sciences

Volumn 86, Issue 3-4, 2010, Pages 124-132

  Yoshida, Junko ^a   Ishibashi, Takaharu ^a   Yang, Mei ^a   Nishio, Matomo ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

A431 cells; Calcium channel blocker; Caveolin 1; Cell proliferation; Cholesterol; Epidermal growth factor receptor; Tyrosine phosphorylation

Indexed keywords

AMLODIPINE; CAVEOLIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; EGFR PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL MEMBRANE; CONTROLLED STUDY; CROSS LINKING; ENZYME ACTIVE SITE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MALE; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TUMOR; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL PROLIFERATION; CELL SURVIVAL; CULTURE TECHNIQUE; DRUG EFFECT; DRUG SCREENING; METABOLISM; PATHOLOGY; PHOSPHORYLATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; TUMOR CELL LINE;

MUS;

AMLODIPINE; ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CALCIUM CHANNEL BLOCKERS; CARCINOMA, SQUAMOUS CELL; CAVEOLIN 1; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHOLESTEROL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; IMMUNOPRECIPITATION; MALE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 73549121289     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2009.11.014     Document Type: Article

References (45)

1. Adachi S, Nagao T, Ingolfsson HI, Maxfield FR, Andersen OS, Kopelovich L, Weinstein IB. The inhibitory effect of (-)-epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells. Cancer Research 2007, 67:6493-6501.
2. Alicia S, Angelica Z, Carlos S, Alfonso S, Vaca L. STIM1 converts TRPC1 from a receptor-operated to a store-operated channel: moving TRPC1 in and out of lipid rafts. Cell Calcium 2008, 44:479-491.
3. Ambudkar IS, Brazer SC, Liu X, Lockwich T, Singh B. Plasma membrane localization of TRPC channels: role of caveolar lipid rafts. Novartis Foundation Symposium 2004, 258:63-70.
4. Batova S, DeWever J, Godfraind T, Balligand JL, Dessy C, Feron O. The calcium channel blocker amlodipine promotes the unclamping of eNOS from caveolin in endothelial cells. Cardiovascular Research 2006, 71:478-485.
5. 2+ influx channels by regulating plasma membrane localization of TRPC1. Journal of Biological Chemistry 2003, 278:27208-27215.
6. Brownlow SL, Sage SO. Transient receptor potential protein subunit assembly and membrane distribution in human platelets. Thrombosis and Haemostasis 2005, 94:839-845.
7. Brownlow SL, Harper AG, Harper MT, Sage SO. A role for hTRPC1 and lipid raft domains in store-mediated calcium entry in human platelets. Cell Calcium 2004, 35:107-113.
8. Christian AE, Haynes MP, Phillips MC, Rothblat GH. Use of cyclodextrins for manipulating cellular cholesterol content. Journal of Lipid Research 1997, 38:2264-2272.
9. Clapham DE. TRP channels as cellular sensors. Nature 2003, 426:517-524.
10. Couet J, Sargiacomo M, Lisanti MP. Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. Journal of Biological Chemistry 1997, 272:30429-30438.
11. Ferguson KM. Active and inactive conformations of the epidermal growth factor receptor. Biochemical Society Transactions 2004, 32:742-745.
12. Jensen RL, Wurster RD. Calcium channel antagonists inhibit growth of subcutaneous xenograft meningiomas in nude mice. Surgical Neurology 2001, 55:275-283.
13. Kahl CR, Means AR. Regulation of cell cycle progression by calcium/calmodulin-dependent pathways. Endocrine Reviews 2003, 24:719-736.
14. Kahn MB, Boesze-Battaglia K, Stepp DW, Petrov A, Huang Y, Mason RP, Tulenko TN. Influence of serum cholesterol on atherogenesis and intimal hyperplasia after angioplasty: inhibition by amlodipine. American Journal of Physiology - Heart and Circulatory Physiology 2005, 288:H591-H600.
15. 2+ entry and respiratory burst: correlations with calcium channel raft trafficking. Journal of Immunology 2007, 178:5253-5261.
16. Kim YN, Wiepz GJ, Guadarrama AG, Bertics PJ. Epidermal growth factor-stimulated tyrosine phosphorylation of caveolin-1. Enhanced caveolin-1 tyrosine phosphorylation following aberrant epidermal growth factor receptor status. Journal of Biological Chemistry 2000, 275:7481-7491.
17. Kim YN, Dam P, Bertics PJ. Caveolin-1 phosphorylation in human squamous and epidermoid carcinoma cells: dependence on ErbB1 expression and Src activation. Experimental Cell Research 2002, 280:134-147.
18. 2+ influx by binding of its scaffolding domain to transient receptor potential channel-1 in endothelial cells. Molecular Pharmacology 2006, 70:1174-1183.
19. Lee H, Volonte D, Galbiati F, Iyengar P, Lublin DM, Bregman DB, Wilson MT, Campos-Gonzalez R, Bouzahzah B, Pestell RG, Scherer PE, Lisanti MP. Constitutive and growth factor-regulated phosphorylation of caveolin-1 occurs at the same site (Tyr-14) in vivo: identification of a c-Src/Cav-1/Grb7 signaling cassette. Molecular Endocrinology 2000, 14:1750-1775.
20. Li YC, Park MJ, Ye SK, Kim CW, Kim YN. Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. American Journal of Pathology 2006, 168:1107-1118.
21. Liao Y, Asakura M, Takashima S, Kato H, Asano Y, Shintani Y, Minamino T, Tomoike H, Hori M, Kitakaze M. Amlodipine ameliorates myocardial hypertrophy by inhibiting EGFR phosphorylation. Biochemical and Biophysical Research Communication 2005, 327:1083-1087.
22. Mancini GB. Antiatherosclerotic effects of calcium channel blockers. Progress in Cardiovascular Diseases 2002, 45:1-20.
23. Mason RP, Campbell SF, Wang SD, Herbette LG. Comparison of location and binding for the positively charged 1, 4-dihydropyridine calcium channel antagonist amlodipine with uncharged drugs of this class in cardiac membranes. Molecular Pharmacology 1989, 36:634-640.
24. 2+ channel blockers to the membrane lipid bilayer. Molecular Pharmacology 1992, 41:315-321.
25. Mason RP, Marche P, Hintze TH. Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arteriosclerosis Thrombosis and Vascular Biology 2003, 23:2155-2163.
26. Meredith PA, Elliott HL. Clinical pharmacokinetics of amlodipine. Clinical Pharmacokinetics 1992, 22:22-31.
27. Mineo C, Gill GN, Anderson RG. Regulated migration of epidermal growth factor receptor from caveolae. Journal of Biological Chemistry 1999, 274:30636-30643.
28. Moolenaar WH, Aerts RJ, Tertoolen LG, De Laat SW. The epidermal growth factor-induced calcium signal in A431 cells. Journal of Biological Chemistry 1986, 261:279-284.
29. 2+ entry (SOCE). Journal of Biological Chemistry 2008, 283:17333-17340.
30. Patel HH, Zhang S, Murray F, Suda RY, Head BP, Yokoyama U, Swaney JS, Niesman IR, Schermuly RT, Pullamsetti SS, Thistlethwaite PA, Miyanohara A, Farquhar MG, Yuan JX, Insel PA. Increased smooth muscle cell expression of caveolin-1 and caveolae contribute to the pathophysiology of idiopathic pulmonary arterial hypertension. FASEB Journal 2007, 21:2970-2979.
31. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, Riley W. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000, 102:1503-1510.
32. Razani B, Woodman SE, Lisanti MP. Caveolae: from cell biology to animal physiology. Pharmacological Reviews 2002, 54:431-467.
33. Ringerike T, Blystad FD, Levy FO, Madshus IH, Stang E. Cholesterol is important in control of EGF receptor kinase activity but EGF receptors are not concentrated in caveolae. Journal of Cell Science 2002, 115:1331-1340.
34. Rybalchenko V, Prevarskaya N, Van Coppenolle F, Legrand G, Lemonnier L, Le Bourihis X, Skryma R. Verapamil inhibits proliferation of LNCaP human prostate cancer cells influencing K+ channel gating. Molecular Pharmacology 2001, 59:1376-1387.
35. Sako Y, Minoghchi S, Yanagida T. Single-molecule imaging of EGFR signalling on the surface of living cells. Nature Cell Biology 2000, 2:168-172.
36. Solomon KR, Mallory MA, Finberg RW. Determination of the non-ionic detergent insolubility and phosphoprotein associations of glycosylphosphatidylinositol-anchored proteins expressed on T cells. Biochemical Journal 1998, 334(Pt 2):325-333.
37. Taylor JM, Simpson RU. Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse. Cancer Research 1992, 52:2413-2418.
38. Yoshida J, Ishibashi T, Nishio M. Growth-inhibitory effect of a streptococcal antitumor glycoprotein on human epidermoid carcinoma A431 cells: involvement of dephosphorylation of epidermal growth factor receptor. Cancer Research 2001, 61:6151-6157.
39. 2+ channel blockers on human epidermoid carcinoma A431 cells. European Journal of Pharmacology 2003, 472:23-31.
40. 2+ channel blocker, on human epidermoid carcinoma A431 cells in vitro and in vivo. European Journal of Pharmacology 2004, 492:103-112.
41. 2+ entries and mRNA expression for TRPC1 and TRPC5 channels in human epidermoid carcinoma A431 cells. European Journal of Pharmacology 2005, 510:217-222.
42. 2+ channel blocker, in human epidermoid carcinoma A431 cells. Biochemical Pharmacology 2007, 73:943-953.
43. Yu X, Sharma KD, Takahashi T, Iwamoto R, Mekada E. Ligand-independent dimer formation of epidermal growth factor receptor (EGFR) is a step separable from ligand-induced EGFR signaling. Molecular Biology of the Cell 2002, 13:2547-2557.
44. Zhuang L, Lin J, Lu ML, Solomon KR, Freeman MR. Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Research 2002, 62:2227-2231.
45. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. Journal of Clinical Investigation 2005, 115:959-968.